Eton Pharmaceuticals Says FDA Review Expected To Take 10 Months, Potential Q1 2026 Launch
ReutersApr 28, 2025 11:08 AM
April 28 (Reuters) - Eton Pharmaceuticals Inc ETON.O:
ETON PHARMACEUTICALS ANNOUNCES SUBMISSION OF NDA FOR ET-600 (DESMOPRESSIN ORAL SOLUTION)
ETON PHARMACEUTICALS INC - FDA REVIEW EXPECTED TO TAKE 10 MONTHS, POTENTIAL Q1 2026 LAUNCH
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Silver Faces Sixth Consecutive Year of Supply Deficit, How Much Upside Is Left in 2026?
TradingKey - According to the 2026 Silver Market Outlook recently released by the Silver Institute, the current robust performance of the silver market remains supported by solid fundamentals. The report indicates that the global silver market is expected to face a structural supply-demand imbalanceTradingKey
12 hours ago
Retail Trading Hub Robinhood Sinks Again, Slumping Over 7% After Hours, Signaling Lack of Interest in Crypto?
TradingKey - Robinhood (HOOD) reported a 34% decline in fourth-quarter net profit to $605 million, with total revenue of $1.28 billion missing Wall Street expectations.TradingKey
13 hours ago
After $20B Debt Sale, Google’s Rare 100-Year Bond Sparks Scrutiny: Has AI Drained the Tech Giant’s Coffers?
TradingKey - According to a Financial Times report, Google parent Alphabet (GOOG)(GOOGL) is planning to issue bonds denominated in British pounds and Swiss francs, which may include the first 100-year GBP bond of this century.TradingKey
Tue, Feb 10
SpaceX IPO Approaching: Will EchoStar Be a Good Buy in 2026?
TradingKey - Today, EchoStar (SATS) is a hybrid story around legacy consumer communications and a high-profile private space play. As a result of its merger with DISH, the company offers satellite TV services and the wireless brand Boost Mobile, in addition to spectrum assets and wholesale network aTradingKey
Tue, Feb 10
U.S. January Nonfarm Payrolls Preview: Likely to Beat Expectations, but with Limited Impact on US Stocks
TradingKey - Against the backdrop of the U.S. economy demonstrating robust resilience and the coordinated easing of monetary and fiscal policies, the nonfarm payrolls data are likely to beat the market consensus expectations.TradingKey
Mon, Feb 9
